Optimizerx Corp Stock Price, News & Analysis

OptimizeRx Corp. (Nasdaq: OPRX) has been invited to the Bank of America 4th Annual HCIT and Digital Health Symposium on December 9-10, 2020. CEO William Febbo will speak on the panel discussing "Trends in Tech-Enabled Rx Supply Chain." The event will include healthcare-focused Bank of America clients and executives from various sectors, including digital health and private equity. OptimizeRx offers digital health solutions linking healthcare providers and patients, helping improve medication affordability and adherence.

OptimizeRx announces a partnership with Komodo Health to integrate its Healthcare Map with OptimizeRx's digital health platform. This collaboration aims to enhance real-world evidence delivery to healthcare providers, expanding OptimizeRx's audience and improving care through actionable insights. As the COVID-19 pandemic has changed care delivery, the partnership focuses on addressing gaps in timely information for healthcare providers. OptimizeRx aims to leverage this integration to bolster patient and physician experiences, ultimately improving treatment outcomes.

OptimizeRx Corp. (Nasdaq: OPRX) has launched an innovative enhancement to its digital health platform that utilizes real-world data (RWD) and machine learning to deliver therapeutic support directly to clinicians at critical patient care moments. This unprecedented approach aims to improve communication and data accessibility in healthcare, potentially enhancing patient outcomes, especially in complex cases like oncology. OptimizeRx emphasizes the importance of actionable data for effective treatment decisions and aims to improve healthcare systems through its AI-driven capabilities.

OptimizeRx Corp. (Nasdaq: OPRX) has reported a remarkable 217% revenue growth from 2016 to 2019, attributed to its expanding digital health platform. The company earned the 432nd spot on Deloitte’s Technology Fast 500, recognizing fast-growing tech companies in North America. CEO William Febbo emphasized the significance of their digital health solutions and a dedicated team. The recent record revenue of $10.5 million for Q3 2020, reflecting a 110% increase year-over-year, signals continued strong performance in a growing market.

OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Fierce Life Sciences to host a virtual event, Innovate4Outcomes, on December 3, 2020. The event aims to address key healthcare challenges exacerbated by COVID-19, promoting collaboration among industry leaders to enhance patient outcomes. Discussions will focus on supporting providers, the role of clinicians in digital strategies, adoption of patient support programs, and leveraging social media for patient engagement. Attendance is limited to 100 participants.

OptimizeRx Corp. (Nasdaq: OPRX) has appointed Angelo Campano as senior vice president and principal of agency channels to enhance partnerships with healthcare advertising agencies. With over 15 years of experience, Campano aims to drive strategic growth at OptimizeRx, including implementing point-of-care engagement programs for targeted patient populations. His background includes significant achievements in electronic health record (EHR) workflows and marketing at Ogilvy Health. The company's digital health platform connects life sciences with healthcare providers, facilitating medication affordability for patients.

OptimizeRx Corp. (Nasdaq: OPRX) reported significant financial growth for Q3 2020, with revenue increasing by 110% to $10.5 million and gross profit up 99% to $6.0 million. Non-GAAP net income was $1.1 million or $0.07 per share. The cash balance was $12.0 million, down from $14.1 million due to higher working capital investments. The company closed additional enterprise deals worth $3.6 million and expanded its digital health network through partnerships with Higi and Epion Health. Despite a GAAP net loss of $0.3 million, management remains optimistic about future growth.

OptimizeRx Corp. (Nasdaq: OPRX) will host a conference call on November 9, 2020, to discuss its Q3 2020 results, expecting record revenue exceeding $10 million, a 100% increase from the previous year. The call will also cover the growth driven by enterprise deals and the value of its Digital Health Platform. Financial results will be released prior to the call, with a question-and-answer segment to follow. Interested parties can join via toll-free and international dial-in numbers. A replay will be available until November 30, 2020.